Perth-based Epichem, a wholly owned subsidiary of ASX-listed biotech PharmAust, has received a contract extension with a leading US biotechnology company, Unity Biotechnology. The new contract, worth around US$1.65 million out to 2020, means Epichem will continue to provide synthetic and medicinal chemistry expertise to support Unity’s drug discovery projects.
08/06/2018 - 05:46
PharmAust biotech lab gets $1.6m contract extension
By Matt Birney
08/06/2018 - 05:46
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX